November 7, 2018 8:09am
Quarterly results: Alnylam Pharmaceuticals (ALNY -$1.88), Regenxbio (RGNX -$0.26), Voyager Therapeutics (VYGR -$0.46) and Editas Medicine (EDIT -$0.72)
Continuing thematic: “street” expectation – meeting or not
Once we get through quarterly LPS (loss-per-share) financial results <notice I didn’t say – <earnings season>, it will be easier for investors to possibly recognize a short or a near-term view; but my fear is that Q4 numbers aren't going to look much better than the Q3/18 numbers – look at the few who are putting-up nine (9) month numbers.
Members only. Please login.